Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Predictors of Patient Uncertainty Regarding Treatment Options Among End Stage Renal Disease Patients Evaluated for Kidney Transplantation.
L. McPherson,¹ M. Basu,¹ S. Pastan,¹ S. Mohan,² M. Wolf,³ J. Gander,¹ R. Patzer.¹
¹Emory University, Atlanta, GA; ²Columbia University, New York City, NY; ³Northwestern University, Chicago, IL.
Background: Although kidney transplantation (KTx) provides a significant survival benefit over long-term dialysis, many end stage renal disease (ESRD) patients are uncertain or conflicted about…
2016 American Transplant Congress
Evolution of Body Composition and Associations to Glucose Metabolism During the First Year After Kidney Transplantation.
M. von Düring,¹ A. Hartmann,^1,2 J. Bollerslev,^2,4 A. Åsberg,^1,3 K. Godang,⁴ I. Eide,¹ D. Dahle,¹ T. Jenssen.^1,5
¹Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ³School of Pharmacy, University of Oslo, Oslo, Norway; ⁴Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁵Metabolic and Renal Research Group, University of Tromsø, Tromsø, Norway.
Background. The evolution and association between body composition and glucose haemostasis after kidney transplantation has not been elucidated.Methods. We investigated 150 consecutive patients without suspected…
2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
¹University of Utah, Salt Lake City, UT; ²University of Southern California, Los Angeles, CA; ³Barnabas Health, West Orange, NJ; ⁴Novartis Pharmaceuticals Corporation, East Hannover, NJ; ⁵California Pacific Medical Center, San Francisco, CA; ⁶Vanderbilt University, Nashville, TN.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…
2016 American Transplant Congress
Short UK Dialysis Does Not Significantly Impact on Live Donor Kidney Allograft Survival.
A. Bentall,^1,2 M. Jesky,^1,2 R. Borrows,^1,2 R. Johnson,³ S. Ball.^1,2
¹Department of Nephrology, University Hospitals Birmingham, Birmingham, United Kingdom; ²School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; ³NHSBT, Bristol, United Kingdom.
Background. The survival advantage of pre-emptive transplantation (Pre-empTx) in live donor kidney transplantation (LDKTx) was reported by Meier-Kreische (Kidney International, 2000). Dialysis practices differ internationally…
2016 American Transplant Congress
Pregnancy Excludes Women from Successful Living Donor Transplantation.
P. Porrett,¹ B. Bromberger,² S. Hashmi,¹ A. Morrison,¹ D. Sawinski.³
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Surgery, Columbia University, New York, NY; ³Medicine, University of Pennsylvania, Philadelphia, PA.
INTRODUCTION Pregnancy-induced sensitization (PIS) is a barrier to the transplantation of women and contributes significantly to gender disparity in transplantation. We hypothesized that this barrier…
2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
S. Pol,¹ A. Aghemo,² L. Lin,³ R. Hyland,³ C. Yun,³ J. Spellman,³ M. Natha,³ D. Brainard,³ J. McHutchison,³ M. Bourlière,⁴ M. Peck-Radosavljevic,⁶ M. Michael,⁵ M. Colombo.²
¹Hopital Cochin, Paris, France; ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³Gilead Sciences Inc, Foster City; ⁴Hôpital Saint Joseph, Marseilles, France; ⁵Hannover Medical School, Hannover, Germany; ⁶Medical University of Vienna, Vienna, Austria.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…
2016 American Transplant Congress
Comparison of C4d Deposition in Renal Biopsies with Luminex-Based C3d Single Antigen Bead (SAB) Detection.
R. Pelletier,¹ I. Balazs,² P. Adams,³ P. Steller,³ N. DiPaola,⁴ L. Rankin,³ A. Diez,⁵ M. Henry.¹
¹Surgery/Transplant, The Ohio State University Wexner Medical Center, Columbus, OH; ²Discovery Research, Immucor, Inc, Stamford, CT; ³Tissue Typing, The Ohio State University Wexner Medical Center, Columbus, OH; ⁴Methodist Hospital, Houston, TX; ⁵Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH.
Recent interest in characterizing the complement-fixing ability of post-transplant donor specific alloantibodies (DSA) resulted in the enhancement of luminex solid phase alloantibody assays to determine…
2016 American Transplant Congress
Investigating Posttransplant Allo-Donor Specific CD57⁺ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
H. Xu, F. Feng, A. Kirk.
Department of Surgery, Duke University, Durham, NC.
Recent studies have showed correlation between CD4+CD57+PD1- cells and costimulation blockade resistant rejection (CoBRR) in patients treated with belatacept without depletional induction. We have recently…
2016 American Transplant Congress
Cognitive Impairment in Kidney Transplant Recipients.
A. Gupta,¹ D. Johnson,¹ G. Chen,¹ D. Subramaniam,¹ T. Polshak,¹ T. Thomas,¹ T. Schmitt,¹ D. Ladner,² A. Yu,¹ J. Burns.¹
¹University of Kansas Medical Center, Kansas City, KS; ²Northwestern University, Chicago, IL.
Background: Cognitive impairment is highly prevalent in end stage renal disease. The prevalence of cognitive impairment after kidney transplantation and the factors associated with it…